The firm negotiated this settlement to resolve the claims of approximately 4,000 Pradaxa® users who claimed to have been injured by the drug. Risks associated with stroke among atrial fibrillation sufferers. Users utilizing Pradaxa started suffering bleeding by means of this medication. Boehringer Ingelheim Pharmaceuticals, Inc. including its affiliated businesses was driven by the Court to enter into a settlement with 4000 users of this anticoagulant that Napoli Shkolnik legal group was representing. Consequently, Boehringer Ingelheim consented To an amount of $650 million in settlement. Paul and his company ensured at least the wounded users of Pradaxa received warranted fiscal compensation and justice.